Formycon AG (0W4N) Price & Analysis

1 Followers

0W4N Stock Chart & Stats

€18.96

-€0.06(-0.32%)

At close: Jul 30 4:00 PM EDT

€18.96

-€0.06(-0.32%)

Day’s Range― - ―

52-Week Range€15.90 - €26.85

Previous CloseN/A

Volume15.00

Average Volume (3M)3.13K

Market Cap

€329.42M

Enterprise Value€304.89

Total Cash (Recent Filing)€51.78M

Total Debt (Recent Filing)€8.52M

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Nov 12, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.42

Shares Outstanding17,672,928

10 Day Avg. Volume3,737

30 Day Avg. Volume3,131

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.13

Price to Sales (P/S)10.17

P/FCF Ratio-10.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€43.50

Price Target Upside129.43% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€83.60M

Bulls Say, Bears Say

Bulls Say

Low-leverage Balance SheetA structurally low-leverage position gives Formycon financial flexibility to fund development and navigate biotech cycles without urgent refinancing. This supports sustained R&D investment, partnership talks and absorbs episodic losses, preserving strategic optionality over months.

Operating Cash Flow RecoveryA shift to positive operating cash flow indicates improving core operational performance and greater internal funding capacity for programs. Over a multi-month horizon this reduces reliance on external financing and supports ongoing development spend and partner milestone delivery.

Partner-driven Commercial ModelA business model centered on licensing, royalties and partner commercialization limits fixed selling costs and spreads commercialization risk. Durable revenue optionality from milestones, royalties and profit shares aligns incentives and enables scaling without building a global salesforce.

Bears Say

Sustained Revenue DeclineConsecutive revenue contractions weaken the base for partner royalties and milestone economics, reducing cash inflows available for R&D and operations. If this structural decline continues over months it undermines operating leverage and puts pressure on contract renegotiations.

Deep Negative Free Cash FlowPersistently negative free cash flow signals that operating inflows don't cover investment and working capital needs, creating a funding gap. Over a medium-term horizon this raises the probability of external financing, partner prepayments or dilution, stressing long-term stability.

Profitability VolatilityLarge swings between profit and loss make forecasting cash generation and partner payouts unreliable. Structural earnings volatility can erode equity, complicate long-term planning and weaken negotiating leverage with partners and suppliers over the coming months.

Formycon AG News

Yi Chen Reiterates Buy on Formycon, Citing Strong Biosimilar Momentum and DCF-Backed €36 Price Target

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Formycon AG, with a price target of...

1d ago

Yi Chen Maintains Buy on Formycon, Trims Price Target to €36 on Strong EBITDA and Biosimilar Pipeline Momentum

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Formycon AG. The associated price target...

4M ago

Formycon: FYB206 Clinical Progress, Strategic Partnerships, and Keytruda Biosimilar Upside Support Buy Rating

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Formycon AG and keeping the price target...

6M ago

Strategic Partnerships and Market Expansion Drive Buy Rating for Formycon AG

Formycon AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

8M ago

Formycon AG’s Strategic Partnerships and Biosimilar Advancements Drive Buy Rating

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Formycon AG today and set a price target...

9M ago

Formycon AG’s Biosimilar Advancements and Growth Prospects Justify Buy Rating and €40 Price Target

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on FYB stock, giving a Buy rating on...

9M ago

FYB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Formycon AG (FYB) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall Street analysts...

9M ago

Formycon AG: Strategic Advancements and Market Opportunities Drive Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Formycon AG, with...

10M ago

Strategic Developments and Partnerships Boost Formycon AG’s Growth Prospects and Support Buy Rating

Formycon AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

11M ago

Formycon AG: Strategic Positioning and Promising Pipeline Justify Buy Rating and €48 Price Target

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Formycon AG today and set a price target...

12M ago

0W4N FAQ

What was Formycon AG’s price range in the past 12 months?

Formycon AG lowest share price was €15.90 and its highest was €26.85 in the past 12 months.

What is Formycon AG’s market cap?

Formycon AG’s market cap is €329.42M.

When is Formycon AG’s upcoming earnings report date?

Formycon AG’s upcoming earnings report date is Nov 12, 2026 which is in 86 days.

How were Formycon AG’s earnings last quarter?

Formycon AG released its earnings results on Aug 12, 2026. The company reported -€0.83 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.69.

Is Formycon AG overvalued?

According to Wall Street analysts Formycon AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Formycon AG pay dividends?

Formycon AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Formycon AG dividends here

What is Formycon AG’s EPS estimate?

Formycon AG’s EPS estimate is -0.04.

How many shares outstanding does Formycon AG have?

Formycon AG has 17,672,928 shares outstanding.

What happened to Formycon AG’s price movement after its last earnings report?

Formycon AG reported an EPS of -€0.83 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went down -0.211%.

Which hedge fund is a major shareholder of Formycon AG?

Currently, no hedge funds are holding shares in GB:0W4N

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Formycon AG Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-3.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Formycon AG

Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.

Formycon AG (0W4N) Earnings & Revenues

Historic Earnings Reports

0W4N Stock 12 Month Forecast

Average Price Target

€43.50

▲(129.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","25":"€25","34":"€34","43":"€43","52":"€52"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€43.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25,34,43,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,21.46153846153846,23.923076923076923,26.384615384615387,28.846153846153847,31.307692307692307,33.769230769230774,36.23076923076923,38.69230769230769,41.15384615384615,43.61538461538461,46.07692307692308,48.53846153846154,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,20.884615384615383,22.76923076923077,24.653846153846153,26.53846153846154,28.423076923076923,30.307692307692307,32.19230769230769,34.07692307692308,35.96153846153846,37.84615384615385,39.730769230769226,41.61538461538461,{"y":43.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19,20.307692307692307,21.615384615384617,22.923076923076923,24.23076923076923,25.53846153846154,26.846153846153847,28.153846153846153,29.46153846153846,30.76923076923077,32.07692307692308,33.38461538461539,34.69230769230769,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >